Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.
RT002 is the Newark, Calif-based company’s long-acting neuromodulator DaxibotulinumtoxinA for Injection.
First, Revance shares SAKURA Phase 3 study results of RT002.
And second, the company announces it has entered into a license agreement with Fosun Pharma to market RT002 in China.
For more information, visit Revance Therapeutics Inc.
[Source(s): Revance Therapeutics Inc, Business Wire]